Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03605810 · ClinicalTrials.gov registry record
Study to Develop a Tool to Estimate the Kidney Function in Databases Without Laboratory Data
A clinical trial, sponsored by Bayer.
- Completed
- Registry status
- 5,132,200
- Enrollment target
NCT03605810: Completed study, sponsored by Bayer.
NCT03605810 is a clinical trial that has completed, run by Bayer. The registered enrollment target is 5,132,200 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03605810 has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- 5,132,200 participants
- Enrollment target
Study Summary
Scientific analyses are frequently performed on e.g. health insurance databases to study the usage and effectiveness of drugs in real life. Kidney function is known to have an influence on a patients disease development and/or drug levels in blood. However, often direct measures for kidney function are not available in databases. This study plans to develop tools to classify the renal function of patients, which helps scientists to identify patient cohorts (groups of patients sharing same characteristics) for scientific analyses.
Primary Outcome
For numeric models cross-validated performance is measured as correlation via r\*2. Class based performances are measured as cross-validated sensitivities given pre-defined false discovery rates with following definition for positives and negatives: Observed eGFR class X: * positive: eGFR measured at begin of time frame is in class X * negative: eGFR measured at begin of time frame is not in class X Class predicted by model: * positive: eGFR predicted is class X * negative: eGFR predicted i
Interventions
- OTHER No Intervention
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5,132,200 participants |
| Start Date | 2018-07-15 |
| Est. Completion | 2018-12-31 |
What the finished NCT03605810 record still lists
NCT03605810 is an observational study that tracks outcomes without assigning an intervention. Its 5,132,200 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 1 intervention - of which No Intervention is the first listed.
NCT03605810 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03605810 about?
NCT03605810 is a clinical study titled "Study to Develop a Tool to Estimate the Kidney Function in Databases Without Laboratory Data". Scientific analyses are frequently performed on e.g. health insurance databases to study the usage and effectiveness of drugs in real life. Kidney function is known to have an influence on a patients disease development and/or drug levels in blood. However, often direct measures for kidney functio...
What is the current status of trial NCT03605810?
This trial is currently completed. The enrollment target is 5,132,200 participants. The study started on 2018-07-15. Estimated completion is 2018-12-31.
What interventions are being tested in trial NCT03605810?
The interventions under investigation include: No Intervention (OTHER).
Who is sponsoring clinical trial NCT03605810?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02693223 · 3,892,063 participants
Get With the Guidelines-Stroke Registry
- NCT06803498 · 3,000,000 participants
Delivery Room Intervention and Evaluation Network
- NCT03813862 · 2,000,000 participants
Observational Pharmaco-Epidemiology Research & Analysis
- NCT06057181 · 2,000,000 participants
Helix Research Network
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI